Can-Fite BioPharma (NYSE:CANF) & Annovis Bio (NYSE:ANVS) Head to Head Comparison
by Michael Walen · The Markets DailyCan-Fite BioPharma (NYSE:CANF – Get Free Report) and Annovis Bio (NYSE:ANVS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.
Risk & Volatility
Can-Fite BioPharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
Earnings & Valuation
This table compares Can-Fite BioPharma and Annovis Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Can-Fite BioPharma | $667,000.00 | 10.46 | -$7.63 million | ($1.79) | -1.10 |
| Annovis Bio | N/A | N/A | -$56.20 million | ($5.75) | -1.47 |
Can-Fite BioPharma has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Can-Fite BioPharma and Annovis Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Can-Fite BioPharma | -1,027.46% | -113.75% | -69.91% |
| Annovis Bio | N/A | -876.22% | -374.65% |
Analyst Ratings
This is a summary of recent recommendations for Can-Fite BioPharma and Annovis Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Can-Fite BioPharma | 0 | 0 | 1 | 1 | 3.50 |
| Annovis Bio | 0 | 1 | 4 | 1 | 3.00 |
Can-Fite BioPharma currently has a consensus price target of $18.00, suggesting a potential upside of 813.71%. Annovis Bio has a consensus price target of $33.60, suggesting a potential upside of 298.58%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Annovis Bio.
Insider & Institutional Ownership
21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 38.3% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Can-Fite BioPharma beats Annovis Bio on 9 of the 13 factors compared between the two stocks.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.